Sanofi-Aventis to end deal with PDI

Share this article:
Contract sales provider PDI said Sanofi-Aventis would end its $20 million sales agreement with the firm, effective Dec. 1. The deal was set to expire Dec. 31, PDI said. The end of the firm’s Sanofi-Aventis deal comes a month after GlaxoSmithKline decided not to renew a $65 million to $70 million contract with PDI for 2007. In April, AstraZeneca also ended a $65 million to $70 million agreement with PDI, affecting approximately 800 field representatives. PDI “has been significantly impacted” as the world’s top pharma companies re-evaluate their commercial models, CEO Michael Marquad said in a statement. “The decisions our customers have made have been based upon this reassessment and not related to the performance of our sales teams.”
Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.